Leveraging Telehealth for Justice-Involved Individuals: Expanding Access to Mental and Substance Use Disorder Treatment

December 11, 2019
1:00-2:30 pm ET

Lewei (Allison) Lin, MD, MS
David T. Moore, MD, PhD
William Morrone, DO, MPH, DABAM, FACOFP, DAAPM
Welcome and Housekeeping

Melissa Stein, DrPH
Senior Research Associate
Criminal Justice Division
The views, opinions, and content expressed in this presentation and discussion do not necessarily reflect the views, opinions, or policies of the Center for Mental Health Services (CMHS), the Center for Substance Abuse Treatment (CSAT), the Substance Abuse and Mental Health Services Administration (SAMHSA), or the U.S. Department of Health and Human Services (DHHS).
<table>
<thead>
<tr>
<th>Agenda</th>
</tr>
</thead>
</table>
| Welcome | Melissa Stein, DrPH  
Senior Research Associate, Policy Research Associates, Inc. |
| Opening Remarks | Jon Berg  
Senior Public Health Advisor, Center for Substance Abuse Treatment, SAMHSA |
| Presentations | Lewei (Allison) Lin, MD, MS  
Assistant Professor, Department of Psychiatry, University of Michigan Medical School  
Research Investigator, VA Ann Arbor (Michigan) Healthcare System |
| | David T. Moore, MD, PhD  
Assistant Professor of Psychiatry, Yale University School of Medicine  
Director, VISN 1 Clinical Resource Hub, VA Connecticut Healthcare System |
| | William Morrone, DO, MPH, DABAM, FACOFP, DAAPM  
Medical Director, Recovery Pathways, Michigan  
Medical Director, 35th Circuit Shiawassee County Drug Court, Michigan  
Associate Professor, Family and Community Medicine, Michigan State University |
| Q&A | Melissa Stein, DrPH  
Senior Research Associate, Policy Research Associates, Inc. |
Opening Remarks

Jon Berg
Senior Public Health Advisor
Center for Substance Abuse Treatment
SAMHSA
Introducing Today’s Presenters: Lewei (Allison) Lin, MD, MS

• Is an addiction psychiatrist and Assistant Professor in the Department of Psychiatry at University of Michigan Medical School.
• Is a research investigator at the VA Center for Clinical Management Research, Michigan.
• Specializes in telehealth interventions to improve access to evidence-based treatments for substance use disorders, improving access to opioid and other substance use disorder treatment, interventions to promote safer opioid prescribing, improving care for people with co-occurring disorders, and reducing drug overdose.
Introducing Today’s Presenters: David T. Moore, MD, PhD

• Is Assistant Professor of Psychiatry at Yale University School of Medicine.
• Serves as multiple principle investigator (MPI) in the VA Quality Enhancement Research Initiative (QUERI) Consortium to Disseminate and Understand Implementation of Opioid Use Disorder Treatment.
• Attended University of Virginia for undergraduate training, earned MD and PhD degrees at the University of Pennsylvania, and completed residency training in psychiatry at Yale School of Medicine.
• Is Medical Director at Recovery Pathways, Michigan, providing telehealth and face-to-face clinical services for people with substance use disorders in Isabella county, MI, including Saginaw Chippewa tribal members, drug court participants, and those residing in the jail.

• Is an Associate Professor of Family and Community Medicine at Michigan State University and former Program Director of Family Medicine at Synergy Medical Education Alliance with Central Michigan University.

• Serves as investigator in a naloxone distribution program in mid-Michigan.

• Serves as director of the Saginaw Chippewa Tribal Family Court and Commissioner on the Michigan governor’s Impaired Driving Commission.
Dr. Allison Lin
• No financial disclosures.
• I receive funding from NIH, SAMHSA, VHA, and CDC.
• The views expressed in this presentation are solely my own and do not necessarily reflect the position or policy of the Department of Veterans Affairs or any other organization.

Dr. David Moore
• No financial disclosures.
• I receive funding from VHA.
• The views expressed in this presentation are solely my own and do not necessarily reflect the position or policy of the Department of Veterans Affairs or any other organization.

Dr. William Morrone
• No financial disclosures, stocks or options
• I receive funding from my own business, “Recovery Pathways”.
• The views expressed in this presentation are solely my own and do not necessarily reflect the position or policy of the Saginaw Chippewa, Michigan State Court System, SAMHSA, ONCDP, or any other organization.
Telemedicine-delivered Treatment Interventions for Substance Use Disorders

Lewei (Allison) Lin, MD, MS
David T. Moore, MD, PhD

December 11, 2019 Hosted by SAMHSA’s GAINS Center
In This Webinar We Will Discuss

• Current challenges in substance use disorder (SUD) treatment access.
• Evidence for effectiveness of telemedicine for SUD treatment.
• Telemedicine for buprenorphine treatment of opioid use disorder (OUD).
• Telemedicine for OUD treatment in the Department of Veterans Affairs (VA) and specific patient scenarios.
Opioid Overdose Deaths in United States

(Source: Hedegaard, 2017)

---

Synthetic opioids other than methadone

Natural and semisynthetic opioids

Heroin

Methadone

Deaths per 100,000 standard population

(Source: Hedegaard, 2017)
Not Just Opioids, Overdose Deaths...

(Source: Kariisa et al., 2019)
Barriers to SUD Treatment

Stigma
Complex Symptoms of Addiction
Limited Access/Accessibility of Treatment

- No Health Coverage and Could Not Afford Cost: 37.3%
- Not Ready to Stop Using: 24.5%
- Did Not Know Where to Go for Treatment: 9.0%
- Had Health Coverage But Did Not Cover Treatment or Did Not Cover Cost: 8.2%
- No Transportation/Inconvenient: 8.0%
- Might Have Negative Effect on Job: 6.6%
- Could Handle the Problem without Treatment: 6.6%
- Did Not Feel Need for Treatment at the Time: 5.0%

(Source: SAMHSA, 2015)
Challenges for the Incarcerated Population

• High prevalence of substance use.
  ▪ Up to two-thirds of people detained in jail have problems with alcohol or drugs.

• Few people currently receive medication treatment in jails or prisons for opioid and other substance use disorders.

• Risk for overdose is high in first month after release.

(Sources: Karberg and James, 2005, Merrall et al., 2010)
Effects of Treatment

• Treatment initiated during incarceration:
  ▪ Medication treatment reduces substance use and overdose.
  ▪ Those initiated into treatment while incarcerated are more engaged in treatment long-term.

(Source: Brinkley-Rubinstein et al., 2018)
• Hire more SUD providers in low treatment jails/prisons.
• Train non-SUD providers in existing jails/prisons.
• Use telehealth to expand access and reach of treatment to facilities lacking providers.

Likely all of these are needed!
What is Telemedicine?

• Synchronous/live videoconferencing:
  ▪ Connects providers and patients in real time for direct care delivery (most common modality reimbursed).

• Asynchronous/store and forward:
  ▪ Not “real time,” allows for electronic transmission of medical information, such as digital images.

• Other modalities such as telephone, text or web-based interventions not included.
• Random controlled trial of telehealth for depression with medical management and brief supportive counseling:
  ▪ Depression outcomes improved with no difference between telehealth and in-person treatment.
  ▪ There were no differences in drop-out or patient satisfaction, which was high in both conditions.

(Source: Ruskin et al., 2004)
Telemedicine Models for Other Chronic Disease Management

• Telehealth collaborative care management (CCM) for veterans with depression:
  ▪ 3 VA Medical Centers and 11 of their affiliated community clinics were studied.
  ▪ The telemedicine-based CCM model was tailored locally.
  ▪ Over 90% of the community clinics maintained the program after the study.

(Source: Fortney et. al., 2012)
• Literature search included:
  ▪ Published manuscripts and conference abstracts
    o In English
    o From January, 1998 through October, 2018
  ▪ Examinations of real-time videoconference-delivered medication or psychotherapy to treat adults with SUDs
  ▪ Outcomes including substance use, treatment adherence, acceptability of the intervention, and satisfaction with treatment
  ▪ Studies that were randomized, experimental, quasi-experimental, or observational in design
Summary of Studies

• For alcohol use disorder (n = 5)
  ▪ All studies provided a psychotherapy intervention, but no studies included any forms of medication treatment.
  ▪ Mixed findings: Some found lower treatment dropout in telemedicine groups, generally high patient satisfaction. Others found no difference with usual care.

• For opioid use disorder (n = 5)
  ▪ 2 studies delivered psychotherapy to patients at home. Similar outcomes were found on substance use and satisfaction compared to in-person care.
  ▪ 3 non-randomized studies examined use of buprenorphine and methadone, delivered in outpatient treatment. Patients were located at a rural clinic and a physician at a distant site and included other components such as urine toxicology screens.
Evidence for telemedicine effectiveness is robust for mental health and other conditions, but a limited number of studies for SUD exist.

Therapeutic relationships and retention in care were comparable; but, studies were small in size and no non-inferiority studies were conducted.

Need to consider technology, personnel, and other logistics.

Telemedicine may be particularly promising when in-person care is not available.
Use of Telemedicine for SUD in the US

- Claims analysis of privately insured enrollees aged 12 and older with SUD in a large private health plan

- Findings
  - Tele-SUD accounted for 0.1% of all SUD visits.
  - Of the tele-SUD visits, 14.5% were psychotherapy visits, 41.7% were initial evaluations, 32.9% were established patient visits.
  - Tele-SUD is primarily used to complement in-person care and is more often used by those with relatively severe SUD.

(Source: Huskamp, Haiden, et al., 2018)
Counties with No OUD Treatment Providers in the US

- Need providers who are X-waivered to dispense buprenorphine and trained to treat OUD.

(Source: Haffajee et al., 2019)
Effective Treatments for OUD: Medication-assisted Treatment (MAT)

• Opioid agonist medications
  ▪ Methadone
    o Can only be used in Drug Enforcement Administration (DEA)-approved opioid treatment programs.
  ▪ Buprenorphine maintenance (Suboxone®, Subutex®, Sublocade®, etc.)
    o Since 2004, providers are allowed to prescribe in office based setting after obtaining required training.

• Opioid antagonist
  ▪ Long acting naltrexone (Vivitrol®)
MAT Treatment Effectiveness

- Reductions in overdose and overall death rates
- Reductions in opioid use
- Improved HIV and Hepatitis C outcomes
- Recent evidence suggests cost effectiveness and improved quality of life

Medications are the most effective treatment for OUD. Without medication treatment, patients have much higher rates of substance use and overdose rates.

(Sources: Altice et al., 1999; Kenworthy et al., 2017; Norton et al., 2017; Nosyk et al., 2015; Schwartz et al., 2013; Sordo et al., 2017)
Things to Consider in Telemedicine for OUD

- **Induction (initiation) and maintenance** stages of treatment
- **Logistics** of urine drug screens, delivering and administering medications, etc.
- Provision of **therapy** with medication
- **Staff interest and comfort** with telemedicine at patient and provider sites
- **State laws** on prescribing controlled medications
- Federal and state **regulations**
- **Complex patients** who may at times need higher level of care or in-person assessment

Ryan Haight Online Pharmacy Act of 2008

• Regulates prescribing of controlled medications when provider and patient are not in the same location.

• Prescription must be a “valid prescription” issued for legitimate medical purpose in the usual course of professional practice.

• Initial face-to-face evaluation must be conducted unless:
  ▪ The facility where the patient is physically present has its own DEA license.
  ▪ It is a case of a covering provider or emergencies.
  ▪ Other exceptions are present.
• Most patients do not need specialty care from addiction specialists.
• MAT accounts for the majority of the treatment effect.
• Reserve “rare” specialists for consultation and the most complicated patients.
Expanding Step 1 with MAT

- Remove barriers that aren’t written in law or evidence-based.
- Provide incentives: Performance pay.
- Increase support:
  - Virtual X-waiver trainings
  - Project ECHO

Step 1
Addiction-focused medical management
- Primary Care
- General Mental Health

Step 2
SUD Specialty Care
- Addiction specialists
- Addiction groups
- IOPs
- Residential programs
Augmenting Step 1 and Step 2 with Telemedicine

**Step 1**
- Self-management
- Addiction-focused medical management
  - Primary Care
  - General Mental Health

**Step 2**
- SUD Specialty Care
  - Addiction specialists
  - Addiction groups
  - IOPs
  - Residential programs

- Tele-Primary Care Providers (PCP)
- Tele-Mental Health
- Tele-Care Management
- Tele-Specialty Prescribers
- Tele-SUD Cognitive Behavioral Therapy
- Tele-IOP/Groups
What is Needed to Prescribe MAT by Telemedicine?

- DEA-waivered providers
- Nursing/clinical staff
- Prescription Drug Monitoring Programs
- Reliable pharmacies
- Laboratory testing
- Ability to refer to a higher level of care

- Compliance with federal tele-prescribing laws (Ryan Haight Act)
- Compliance with state tele-prescribing laws
Advantages: Filling in Buprenorphine Provider Gaps at Large Clinics

On two occasions, large MAT clinics temporarily lost their providers.

**Bangor Community Based Outpatient Clinic**
- On-site mental health nursing
- On-site SUD groups for aftercare
- Can perform *monitored inductions*:
  - Vital Signs, Clinical Opiate Withdrawal Scale (COWS), and medical backup
  - One clinical video telehealth (CVT) provider can cover a single large population of patients

**Augusta VA Medical Center**
- Ability to store buprenorphine on-site
- On-site inpatient services
Advantages: Covering Three Small Rural Clinics With One MAT Prescriber

- Few buprenorphine providers in local communities
- On-site primary care, nursing, urine drug screen collection, and scheduling
- Unmonitored buprenorphine induction
- CBT for SUD provided via telehealth

Example: 30 year old patient presenting to PCP in opioid withdrawal
Disadvantages: Legal barriers

• New Hampshire law requires that a patient be treated first **in-person** at an opioid treatment program (OTP) prior to tele-prescribing controlled substances.

• State laws can change quickly.
Advantages: Following Patients Where They Live and Work

• One provider can follow a patient as they move throughout the state.

Example: 50 year old patient started on MAT in Caribou, ME
• Moved to Augusta and then Portland for employment
• Returned to Caribou to be closer to family
• Moved around a total of 300 miles
• Seen at 3 VA clinics in 2 months
• Experienced NO DELAYS IN TREATMENT
Summary

• Most of the benefit from opioid treatments come from MAT.
• Tele-MAT is a great way to flexibly increase access to MAT.
• There can be some barriers.
• Providing MAT to remote sites can be rewarding for providers.
References

Telehealth For Criminal Justice & Drug Courts:

35th Circuit Shiawassee Drug Court,
66th District Probation Saginaw Chippewa Tribal Court, Family Court

William Morrone, DO, MPH
DABAM, FACOFP, DAAPM

December 11, 2019
Hosted by SAMHSA’s GAINS Center
• 42 CFR part 2 regulations serve to protect patient records created by federally funded programs for the treatment of substance use disorder (SUD).

• SAMHSA is currently proposing to revise part 2, to facilitate better coordination of care for substance use disorders which will also enhance care for opioid use disorder (OUD).

• These provisions will be an important part of the federal response to the opioid epidemic, while maintaining part 2 confidentiality protections.
What's Not Changing Under the New Part 2

• It will not alter the basic framework for confidentiality protection of SUD patient records created by federally funded programs.

• Part 2 will continue to prohibit law enforcement use of SUD patient records in criminal prosecution against the patient.

• Part 2 will also continue to restrict the disclosure of SUD treatment records without patient consent.
Service Area: Recovery Pathways, Michigan

Recovery Pathways’ Billing Footprint: 458 zip codes

Copyright © 2020 Dr. Morrone
Recovery Pathways in Isabella County, MI

- Face-to-face service at the Community Mental Health Isabella County Center (CMH)
- Telemedicine service in the CMH
- Naltrexone (Vivitrol®) injections in the jail
Drug-related Deaths: 2014-2018

Isabella Drug Related Accidental Deaths from E.W. Sparrow Pathology death certificates 2014-2018

- 2017-2018 Recovery Pathways’ MAT embedded in Isabella County Community Mental Health 302 Crapo, Mt Pleasant, MI (CMH)
- DEA reports Fentanyl Increases Percentage in Michigan Heroin
- Recovery Pathways Opens in Midland CMH

Copyright © 2020 Dr. William Morrone; unpublished data (2019), Bay County Health Department
An originating site: the location where a beneficiary gets physician or practitioner medical services through a telecommunications system.

The beneficiary must go to the originating site for the services located in either:
- A county outside a Metropolitan Statistical Area (MSA).
- A rural Health Professional Shortage Area (HPSA)* in a rural census.

An originating site can be your jail or your Community Mental Health (CMH).

*Health Resources & Services Administration (HRSA) designates HPRA.
Telehealth Originating Site (Continued)

- Physician or Practitioner office
- Hospital
- Critical Access Hospital
- Rural Health Clinic (RHC)
- Federally Qualified Health Center (FQHC)
- Community Mental Health center (CMH)
- Home (support ACT; July 1, 2019)
Distant Site: Physician/Practitioner

- Physician
- Nurse Practitioner and Physician’s Assistant
- Nurse-midwife
- Clinical nurse specialist
- Certified registered nurse anesthetist
- Clinical psychologist (CP), clinical social worker (CSW)
  - CP and CSW cannot bill Medicare for psychiatric diagnosis, evaluation (E&M), and treatment.
Interactive Audio and Video

• Provider must use an interactive audio and video telecommunications system that permits **real-time communication between provider at the distant site and the beneficiary at the originating site.**

• Transmitting medical information to a physician or practitioner who reviews it later is permitted only in Alaska or Hawaii federal telemedicine demonstration programs.

• **WiFi (rate limiting)** + **tablet** + **valid software** are necessary.
Interactive Audio and Video: Screenshot
Drug Court Services

- Must be at a clinical site defined by Centers for Medicare and Medicaid (CMS) telehealth services.

**Diagram:**
- **Drug Court**
  - Originating Site: CMHS, FQHC, RHC, hospital, or home
- **Telehealth Provider**
  - Distant Site: Cannot be FQHC or RHC
Therapeutic Alliance

• **Attitude:**
  - Non-judgmental
  - Curious
  - Empathetic

• **Respectful**
  - Recognize adversity.
  - Recognize strengths.
  - Use non-stigmatizing language.

• **Honesty**

• **Shared goals**
  - Why is the patient seeking treatment?
  - Provider treatment team concerns

• **Reassurance**
  - Assure patient objective is concern for his or her health.
  - Confidentiality (with qualifiers)
    - Safety of self, well-being of other (especially children)

(Source: Miller WR & Rollnick S., 2013.)
SUD in the DSM V

- Loss of Control
  - Larger amounts, over longer time periods
  - Inability to cut back
  - More time spent getting, using, recovering
  - Missed activities
  - Craving

- Physiologic
  - Tolerance and withdrawal

- Consequences
  - Hazardous use
  - Continued use after significant problems
  - Social or interpersonal problems related to use
  - Neglected major roles

- A substance use disorder is defined as having 2 or more of these symptoms in the past year.
- Tolerance and withdrawal alone don’t necessarily imply a disorder.
- Severity is related by the number of symptoms:
  - 2-3 = mild
  - 4-5 = moderate
  - 6+ = severe

---

SAMHSA
Substance Abuse and Mental Health Services Administration
## Telemedicine Billing

<table>
<thead>
<tr>
<th>MAT-SERVICE</th>
<th>HCSPCS/CPT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telehealth Pharmacological Management</td>
<td>G0459</td>
</tr>
<tr>
<td>Alcohol and SUD (not tobacco) structured assessment and intervention</td>
<td>G0396-97</td>
</tr>
<tr>
<td>Interactive complexity psychiatry service</td>
<td>90785</td>
</tr>
<tr>
<td>Psychotherapy for crisis</td>
<td>90839-40</td>
</tr>
</tbody>
</table>
Drug Testing

• Drug testing can be done remotely
• Foil counts: A low tech diversion tool
• Prescription Drug Monitoring Program (PDMP)
• The initial evaluation is comprised of building a therapeutic alliance and obtaining data for treatment planning and initiation.

• Important components include history of medical, psychiatric, and substance use disorders.

• There is great variability in practice and providers and clinics may have their own policies, protocols, and preferences regarding evaluation and documentation.
Continuing Education Statement

This course has been approved by Advocates for Human Potential, Inc. (AHP), as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #81914 is responsible for all aspects of their programming. This webinar is eligible for 1.5 NAADAC continuing education hours (CEH).

Please use the web link provided to complete the evaluation and quiz: https://bit.ly/2Paaaiv. CEH certificates can be downloaded and printed upon completing the quiz.
Additional Resources

Disclosure of Substance Use Disorder Patient Records: Does Part 2 Apply to Me?

Title 42 of the Code of Federal Regulations (CFR) Part 2, Confidentiality of Substance Use Disorder Patient Records (2014) was first promulgated in 1987 to address concerns about the potential use of Substance Use Disorder (SUD) information in non-treatment based settings such as administrative or criminal hearings related to the patient. Part 2 is intended to ensure that a patient receiving treatment for a SUD in a Part 2 Program does not face adverse consequences in relation to issues such as criminal proceedings and domestic proceedings such as those related to child custody, divorce or employment. Part 2 protects the confidentiality of SUD patient records by restricting the circumstances under which Part 2 Programs or other ‘lawful holders’ can disclose such records.

Part 2 Programs are Federal assisted programs. In general, Part 2 Programs are prohibited from disclosing any information that would identify a person as having or having had a SUD unless that person provides written consent. Part 2 specifies a set of requirements for consent forms, including but not limited to the name of the patient, the names of individuals/entities that are permitted to disclose or receive patient identifying information, the amount and kind of the information being disclosed, and the purpose of the disclosure (see §2.31). In addition to Part 2, other provisions such as the Health Insurance Portability and Accountability Act of 1996 (HIPAA) may have been enacted. HIPAA generally permits the disclosure of protected health information for certain purposes without patient authorization, including treatment, payment, or health care operations.

To help stakeholders understand their rights and obligations under Part 2, the Office of the National Coordinator for Health Information Technology (ONC) and the Substance Abuse and Mental Health Services Administration (SAMHSA) have released two fact sheets illustrating how Part 2 might apply in various settings. This fact sheet focuses on helping health care providers determine how Part 2 applies to them (i.e., disclosing scenarios they might encounter when caring for patients). Each scenario describes

1 A ‘lawful holder’ is an individual or entity who has received patient identifying information as a result of a part 2 compliant consent or otherwise permitted under the part 2 statute, regulations, or guidance.

2 ‘Meaningful action’ refers to all SUD programs to disclose protected health information (PHI) to carry out treatment, payment, or health care operations.

3 ‘Program’ defined in 2.31 is an individual entity, rather than a general medical facility, or an identified unit within a general medical facility, that provides treatment, payment, or health care operations.

4 ‘Meaningful action’ refers to all SUD programs to disclose protected health information (PHI) to carry out treatment, payment, or health care operations.

5 ‘Program’ defined in 2.31 is an individual entity, rather than a general medical facility, or an identified unit within a general medical facility, that provides treatment, payment, or health care operations.

6 State laws and regulations may also further restrict the disclosure of substance use disorder patient records. For more information, please contact your state’s health department. The facts about this decision are not exhaustive, and readers are encouraged to seek additional technical guidance to supplement this disclosure information.

Disclosure of Substance Use Disorder Patient Records: How Do I Exchange Part 2 Data?

Title 42 of the Code of Federal Regulations (CFR) Part 2, Confidentiality of Substance Use Disorder Patient Records (2014) was first promulgated in 1987 to address concerns about the potential use of Substance Use Disorder (SUD) information in non-treatment based settings such as administrative or criminal hearings related to the patient. Part 2 is intended to ensure that a patient receiving treatment for a SUD in a Part 2 Program does not face adverse consequences in relation to issues such as criminal proceedings and domestic proceedings such as those related to child custody, divorce or employment. Part 2 protects the confidentiality of SUD patient records by restricting the circumstances under which Part 2 Programs or other ‘lawful holders’ can disclose such records.

Part 2 Programs are Federal assisted programs. In general, Part 2 Programs are prohibited from disclosing any information that would identify a person as having or having had a SUD unless that person provides written consent. Part 2 specifies a set of requirements for consent forms, including but not limited to the name of the patient, the names of individuals/entities that are permitted to disclose or receive patient identifying information, the amount and kind of the information being disclosed, and the purpose of the disclosure (see §2.31). In addition to Part 2, other provisions such as the Health Insurance Portability and Accountability Act of 1996 (HIPAA) have been enacted. HIPAA generally permits the disclosure of protected health information for certain purposes without patient authorization, including treatment, payment, or health care operations.

To help stakeholders understand their rights and obligations under Part 2, the Office of the National Coordinator for Health Information Technology (ONC) and the Substance Abuse and Mental Health Services Administration (SAMHSA) have released two fact sheets illustrating how Part 2 might apply in various settings. This fact sheet demonstrates how Part 2 applies to the electronic exchange of health

healthit.gov
Substance Abuse and Mental Health Services Administration

SAMHSA’s mission is to reduce the impact of substance abuse and mental illness on America’s communities.

www.samhsa.gov
1-877-SAMHSA-7 (1-877-726-4727) • 1-800-487-4889 (TDD)

GAINS Center for Behavioral Health and Justice Transformation

The GAINS Center focuses on expanding access to services for people with mental and/or substance use disorders who come into contact with the justice system.

https://www.samhsa.gov/gains-center
1-800-311-4246